KBY Biotech Indexv0.0.34
Search
← Pipeline|Tirainavolisib

Tirainavolisib

Phase 3
CON-4041
By ContraFect (Phibro)
Source: Trial-derived·Trials: 4
Modality
ERT
MOA
CAR-T CD19
Target
FLT3
Pathway
Incretin
Parkinson's
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
Nov 2018
→ Dec 2031
Phase 3Current
NCT06167099
425 pts·Parkinson's
2024-11→2028-11·Recruiting
NCT04146896
2,566 pts·Parkinson's
2018-11→2030-10·Not yet recruiting
NCT05816714
514 pts·Parkinson's
2021-02→2028-08·Terminated
+1 more trial
4,956 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2028-08-182.4y awayPh3 Readout· Parkinson's
2028-11-022.6y awayPh3 Readout· Parkinson's
2030-10-094.5y awayPh3 Readout· Parkinson's
2031-12-055.7y awayPh3 Readout· Parkinson's
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Termina…
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2028-08-18 · 2.4y away
Parkinson's
Ph3 Readout
2028-11-02 · 2.6y away
Parkinson's
Ph3 Readout
2030-10-09 · 4.5y away
Parkinson's
Ph3 Readout
2031-12-05 · 5.7y away
Parkinson's
RecruitingActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT06167099Phase 3Parkinson'sRecruiting4256MWD
NCT04146896Phase 3Parkinson'sNot yet recr...2566DAS28
NCT05816714Phase 3Parkinson'sTerminated514MRD
NCT05538725Phase 3Parkinson'sActive1451Safety
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-8168Johnson & JohnsonPhase 2/3FLT3GLP-1/GIP
RHH-1546RochePhase 2/3C5CAR-T CD19
DatoglumideAbbVieApprovedCFTRCAR-T CD19
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
SotorapivirModernaApprovedFLT3TYK2i
BII-4342BiogenPhase 2/3CGRPCAR-T CD19
TalasotorasibExelixisPreclinicalAPOC3CAR-T CD19
NidaratamabExelixisPhase 3FLT3AHRant
ElracapivasertibKymeraPhase 3PRMT5CAR-T CD19
ZanumavacamtenIovancePhase 2FLT3BCL-2i